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A B S T R A C T
1,25-dihydroxyvitamin D3 (1,25D), a steroid hormone which regulates calcium/phosphate homeostasis,
has a broad spectrum of anti-cancer activities, including differentiation of acute myeloid leukemia (AML)
cells. In order to avoid undesirable side effects such as hypercalcemia, low-calcemic analogues should be
produced for therapeutic purposes. In this paper, we describe biological activities of double-point
modiﬁed analogues of vitamin D2 and we compare them to 1,25D and to paricalcitol, the drug used to
treat secondary hyperparathyroidism. In vivo, our new analogues have lower calcemic effects, and lower
toxicity in comparison to 1,25D. They have enhanced pro-differentiating and transcription-inducing
activities in AML cells. Interestingly, differentiation effects do not correlate with the afﬁnities of the
analogues to the vitamin D receptor (VDR).
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1,25-dihydroxyvitamin D3 (1,25D), a well known anti-rachitic
agent [1], also has antitumor and pro-differentiating activities
towards cancer cells [2,3]. This is why many 1,25D analogues with
improved anti-proliferative and pro-differentiating activities, as
well as lower calcemic effects have been designed [4,5].
Mechanistic studies of 1,25D analogues provide important
information that allow us to determine which structural mod-
iﬁcations of the 1,25D molecule are responsible for their changed
biological properties. 1,25D exerts most of its biological functions
via the vitamin D receptor (VDR) [6]. Many of VDR target genes are
connected with the calcium/phosphate homeostasis, but also with
anti-proliferative and pro-differentiating actions of 1,25D in non-
calcemic tissues. CYP24A1, the gene most strongly regulated by
VDR, encodes an enzyme responsible for degradation of 1,25D [7].
Another primary VDR-target gene is CD14, a monocytic cell
differentiation marker, and a co-receptor for bacterial lipopolysac-
charide, characteristic for monocytes and macrophages [8,9].
It has been long believed in the ﬁeld that only subtle changes to
the structure of vitamin D might result in beneﬁcial changes in the
activity proﬁle. Therefore, all the vitamin D drug substances were
modiﬁed in a single point of the molecule. This is why in our search
for vitamin D analogues of selective activity proﬁle we modiﬁed up
to now the molecule exclusively in the aliphatic side-chain. The
most active analogues we obtained contained one-carbon unit
extended (24a-homo) and rigidiﬁed (conjugated diene) side-chain
(PRI-1906), additionally homologated at both terminal carbons
(PRI-1907).
In our attempt to lower the toxicity of our PRI-1907 and to
increase its biological activity we have now synthesised new
generation of analogues of 1,25-dihydroxyvitamin D2 modiﬁed in
two distinct parts of molecule. In these structures we have
combined our optimised side-chain of PRI-1906 and PRI-1907
[10–12] with the known 19-nor modiﬁcation. This modiﬁcation
was previously introduced in the structure of a drug substance
(paricalcitol, PRI-5100) and its 24-epi analogue (PRI-5101) [13], and
we use them as a reference in our experiments. In this paper weFig. 1. Structures of 1,25D, PRI-1907, PRIpresent our in vivo and in vitro evaluation of the resulting
analogues PRI-5201 and PRI-5202 compared to the previously
obtained ones and to 1,25D. The structures of the analogues are
presented in Fig. 1.
2. Materials and methods
2.1. Chemicals and antibodies
1,25D and analogues were synthesised at the Pharmaceutical
Research Institute (Warsaw, Poland). Antibodies for ﬂow cytom-
etry were from ImmunoTools (Friesoythe, Germany). Antibodies
for western blots and chemiluminescence blotting substrate were
from Santa Cruz (Santa Cruz, CA).
2.2. Cell lines, ﬂow cytometry and western blots
HL60 cells (Institute of Immunology and Experimental Therapy
in Wroclaw, Poland) and HaCat cells (Dr. Miguel Quintanilla,
Instituto de Investigaciones Biomedicas Alberto Sols, Madrid,
Spain) were cultured using standard conditions. HL60 cells were
incubated, labeled and analysed by ﬂow cytometry as we have
described before [10]. Western blotting was performed using
nuclear fractions from cells as previously described [10].
2.3. cDNA synthesis and real time PCR
Total RNA was isolated and transcribed into cDNA. Then Real
time PCR reaction was performed as previously described [10].
2.4. Human VDR binding assay
Binding afﬁnity to VDR was evaluated using a PolarScreenTM
Vitamin D Receptor Competitor Assay Kit under manufacturer
conditions (Life Technologies). The polarised ﬂuorescence was
measured using Envision (PerkinElmer). All compounds were
evaluated within the range 1011–105M, IC50 values were
calculated using the average of values obtained.-5100, PRI-5101, PRI-5201, PRI-5202.
Table. 1
VDR binding and differentiation-inducing activities of 1,25D and analogues PRI-
1907, PRI-5100, PRI-5101, PRI-5201 and PRI-5202.
VDR Binding Differentiation
IC50 (M) RBAa EC50 (M) EMR
1,25D 2.320 e009 100 5.347 e010 1
PRI-1907 6.172 e009 37 5.952 e011 0.11
PRI-5100 5.599 e010 414 1.128 e009 2.12
PRI-5101 4.921 e010 471 1.179e009 2.22
PRI-5201 1.193 e009 194 3.397 e011 0.063
PRI-5202 3.598 e009 64 1.788e011 0.033
The VDR binding afﬁnity is expressed as IC50 and percentage activity.
a The potency of 1,25D is normalised to 100. RBA: relative binding afﬁnity. Cell
differentiation activity is expressed as EC50 and EMR: effective molar ratio (EC50
analogue/EC50 1,25D).
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All animals studies were approved by the University of Santiago
de Compostela Ethics Committee for Animal Experiments. Male
CD-1 mice (age matched, between 6 and 8 weeks) were obtained
from Charles River Laboratories (L’Arbresle, France). The com-
pounds were resuspended in sesame oil and administered
intraperitoneally (0.3 mg/kg) every other day for 21 days. Ethanol
resuspended in sesame oil was used as the control for this
experiment. Serum calcium levels were measured a day after the
last dose using the QuantiChom Calcium Assay Kit (BioAssay
Systems, Hayward, CA, USA) following manufacturer’s guidelines.
The weight of mice was measured every week.
2.6. Statistical analysis
All experiments were repeated at least three times. Values are
expressed as means  SD. Dose response curves for cell differenti-
ation and competitive VDR binding, calculation of EC50 and IC50
values, as well as analysis of statistical signiﬁcance (ANOVA
followed by t-tests) were performed using GraphPad Prism 6
software (San Diego, CA, USA).
3. Results
3.1. Calcemic activities in vivo
First, we tested calcemic activities of our compounds in mice.
The calcium serum levels induced by 1,25D and by all analogues,
compared to the vehicle (ethanol) treated mice, are presented in
Fig. 2A. Since toxic effects are not always directly connected to
calcemia induced by 1,25D or by the analogues, we also examined
the extent to which administration of the compounds affected the
body weight of mice. The changes in body weight are related to
overall toxicity (Fig. 2B). The results show that all of the tested
analogues are less calcemic than 1,25D. The analogues PRI-1907,
and to lower extent PRI-5202, exerted some general toxicity,
similarly to 1,25D, as they affected weight gain of the mice. It is
noteworthy, that mice receiving analogue PRI-5201, showed no
signiﬁcant change in body weight when compared to vehicle-
treated mice.Fig. 2. In vivo effects of 1,25D and analogues.
A. Calcium levels in mice treated with the natural hormone 1,25D and compounds. Five m
day during 3 weeks, and calcium levels were measured on day 21. Error bars represent the
of analogues on body weight of mice. Mice were weighed every other day for 3 weeks. An
###P  0.001, ####P  0.0001, ns P > 0.05.3.2. Binding of analogues to VDR
Since VDR is the primary target for 1,25D and analogues in cells,
it is important to study the afﬁnities of given analogues to this
protein [14]. The experiments were performed using a ﬂuores-
cence polarisation (FP)-based competition assay. The binding of
analogues to VDR was tested over a wide range of concentrations
and was compared to binding of 1,25D to the receptor. Dose–
response curves were plotted (data not shown), and IC50 values
were calculated from these dose–response curves (Table 1).
3.3. Differentiation of HL60 cells
HL60 cells were used to determine how the subtle changes
introduced to the structure of analogues inﬂuenced their pro-
differentiating activities [15,16]. The cells were exposed to
compounds at a wide concentration range for 96 h and then the
expression of monocyte/macrophage differentiation markers
CD11b and CD14 was studied using ﬂow cytometry. Since treated
cells expressed CD14 at a greater extent than CD11b, we therefore
present the data obtained for this differentiation marker. Dose–
response curves allowed us to calculate EC50 value for each
analogue (Table 1). This data conﬁrmed our earlier ﬁndings that
analogue PRI-1907 is about one order of magnitude more active
than 1,25D [10,12], and it also shows that the new analogues, PRI-
5201 and PRI-5202 are even more active in inducing AML cell
differentiation than PRI-1907.ice per group were treated with 0.3 mg/kg of analogues, 1,25D or control every other
 standard deviation (SD). Analogues were compared to 1,25D, ****P  0.0001. B. Effect
alogues were compared to either the control (#) or to 1,25D (*) *P  0.05, **P  0.01,
Fig. 3. Impact of 1,25D and analogues on mRNA levels.
A. HL60 cells were exposed to 1 nM 1,25D and analogues for 96 h and then the expression of CYP24A1 mRNA was tested in Real Time PCR. The graph shows mean values
(SEM) of fold changes in CYP24A1 mRNA levels relative to GAPDH. B. HL60 cells were exposed to 1 nM 1,25D and analogues for 48 h and then the expression of CD14 mRNA
was tested in Real Time PCR. The graph shows mean values (SEM) of fold changes in CD14 mRNA levels relative to GAPDH.
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1,25D and its analogues are ligands of VDR, a receptor which is
a ligand-activated transcription factor. The activity of analogues
can be measured by the levels of transcription which they induce.
In order to compare the transcriptional activities of the analogues
we tested the expression of CYP24A1 and CD14 genes in HL60
cells exposed for 48 h (CD14) and 96 h (CYP24A1) to the analogues
at 1 nM and 10 nM (not shown) concentrations. The results of
CYP24A1 expression are presented in Fig. 3A, and CD14
expression in Fig. 3B. Again, the analogues PRI-1907, PRI-5201
and PRI-5202 are more active than 1,25D, especially at 1 nM
concentrations.
3.5. Nuclear translocation and accumulation of VDR in response to
analogues
The ligand-induced translocation of VDR into the nucleus is a
critical step required for transcriptional activity of VDR [17]. Given
that VDR nuclear accumulation and pro-differentiating activity
were correlated for previously tested analogues, we therefore
studied how new analogues inﬂuence the levels of VDR protein in
HL60 cells. We analysed VDR levels in nuclear fractions of cellsFig. 4. Nuclear localisation of VDR protein in HL60 exposed to 1,25D or analogues.
HL60 cells were exposed to 1,25D or analogues at 1 nM concentration for 3 h and 72 hexposed for different times to analogues at 1 nM concentration.
Actin was used as a control, as it is a protein that does not change
during HL60 cell differentiation. A signiﬁcant increase in the level
of VDR in the nucleus was seen as early as 3 h after exposing the
cells to analogues, but at this time-point the VDR level does not
correlate with differentiation-inducing activity of the given
analogue. At later time-points, from 24 h (not shown) to 72 h post
treatment, the amount of VDR in the nucleus correlates with the
differentiation effect (Fig. 4).
3.6. Activation of C/EBPb by 1,25D and analogues
In addition, we have examined the ability of tested analogues to
increase expression of C/EBPb protein. Our previous studies
provided strong experimental evidence that 1,25D up-regulates
expression of this protein in HL60 cells [18] and, it has been shown
that down-regulation of C/EBPb protein levels, using antisense
technology, attenuates 1,25D-induced differentiation in this cell
line [19,20]. C/EBPb expression in response to 1,25D treatment is
undetectable at 24 h but it rises gradually to reach maximal levels
at 3–4 days of treatment [18]. Therefore, we determined C/EBPb
protein levels in nuclear fractions of HL60 cells treated for 72 h
with 1 nM 1,25D and analogues. The results are presented as and then expression of VDR was determined in the nuclear fractions.
Fig. 5. C/EBPb isoforms in HL60 cells treated with 1 nM 1,25D and analogues.
HL60 cells were treated for 72 h with 1 nM 1,25D and analogues. The nuclear fraction was separated by electrophoresis and transferred onto PVDF membrane, and probed with
antibodies against C/EBPb, and b-actin as fractionation/loading controls. In addition to the three C/EBPb isoforms, unidentiﬁed bands, possibly cleavage products of C/EBPb,
are present.
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expression of C/EBPb2 and C/EBPb3 correlates well with the ﬁnal
cell differentiation effect.
3.7. Pro-differentiating activity of analogues towards human
keratinocytes
In order to determine whether the increased potency of
analogues was limited to AML cells, we tested the differentiation
effects of analogues towards human keratinocyte cell line HaCat
[21]. After exposure to 1,25D and to other VDR ligands these cells
change their growth properties and phenotype. This experiment
showed in a qualitative manner the ability of analogues to induce
differentiation of keratinocytes. The results presented in Fig. 6
show that all the analogues induced phenotype changes to the
HaCat cells which are characteristic for differentiated cells.
4. Discussion
1,25D is a very active compound with many biological activities,
including induction of cell differentiation, immunomodulation and
inhibition of cell proliferation [2,3,22]. 1,25D is also a potent
regulator of calcium/phosphate metabolism, so when used at
pharmacological concentrations, it can induce hypercalcemia [1].
To utilise the therapeutic properties of 1,25D, it is necessary to
obtain analogues that would have increased beneﬁts to risk ratio,
as compared to 1,25D [5]. The analogues should be selective and
should have increased pro-differentiating and anti-proliferative,
and lowered calcemic activities. Regulation of the effective
concentration and biological activity of 1,25D is maintained at
multiple levels including transport of the analogue to the cell,
intracellular localisation of the receptor, effective activation of
transcription and degradation of 1,25D to inactive metabolites
[23]. Therefore, it is necessary to complete a wide range of
experiments to fully characterise new vitamin D analogues.Fig. 6. Differentiation of HaCat cells in response to 1,25D or analogues.
Phase-contrast micrographs showing the induction by analogues of a differentiated a
analogues at 100 nM for 48 h.Our experiments revealed that the new, double-point modiﬁed
analogues do not increase serum calcium levels as much as 1,25D.
Their toxic effects, displayed as their ability to inﬂuence mice body
weight, are lower than that of 1,25D, and also lower than toxicity
induced by PRI-1907, the most active compound out of the single-
point modiﬁed vitamin D2 analogues. The pro-differentiating
activities of PRI-5201 and PRI-5202 are more than an order of
magnitude higher than that of 1,25D which suggests that they can
be applied at lower concentrations to obtain anti-cancer or
immunomodulatory effects. New, toxicological screening of these
analogues, in a broader range of concentrations should reveal
whether they are suitable for long-term therapy.
In our previous experiments, we have shown that the high
differentiation-inducing potential of PRI-1907 correlated with its
ability to increase the expression of the master regulator of
monocyte differentiation, namely the C/EBPb transcription factor
and with upregulation of VDR target CD14 gene. The same
correlation was observed for double-point modiﬁed analogues
(PRI-5201 and PRI-5202). The high pro-differentiating activities of
PRI-5201 and PRI-5202, as compared to PRI-5100 and PRI-5101,
cannot be explained by the binding afﬁnities of these analogues for
VDR. The afﬁnity of PRI-5100 and PRI-5101 is more than four times
higher than that of 1,25D. Interestingly, the afﬁnity of PRI-5101,
with the unnatural conﬁguration at C-24 in the side-chain, is
higher than that of PRI-5100 with the natural side-chain of 1,25-
dihydroxyvitamin D2. The afﬁnity of the new analogue PRI-5201 is
two times lower than that of PRI-5100 and the afﬁnity of PRI-5202
is about seven times lower than that of PRI-5100 and PRI-5101.
Therefore, we suggest that an interplay of different signal
transduction pathways, genomic and non-genomic events, and
the ability of given analogue to stabilise VDR in the cell nucleus of
target cells (see Fig. 4) are all important to eventual biological
activity. The combination of selected structural fragments (side-
chain of analogue PRI-1907 and 19-nor modiﬁcation) has been
shown to be very beneﬁcial to the activity proﬁle of vitamin Ddhesive epithelial phenotype in human HaCat cells. The cells were treated with
A. Corcoran et al. / Journal of Steroid Biochemistry & Molecular Biology 164 (2016) 66–71 71analogues. Until now analogues PRI-5201 and PRI-5202 represent
the most active vitamin D compounds we designed, synthesised
and biologically evaluated. Further modiﬁcations of the vitamin D
structure leading to the same direction as to biological activity are
under way in our laboratories.
Acknowledgements
The research leading to these results has received funding from
the People Program (Marie Curie Actions) of the European Union’s
Seventh Framework Program FP7/2007-2013 under REA grant
agreement number 315902. AC gratefully acknowledges her
receipt of a Marie Curie Research Associate post. EM, GB and AK
are partners within the Marie Curie Initial Training Network
DECIDE (Decision-making within cells and differentiation entities
therapies). This work was presented at the 18th Workshop on
Vitamin D, in Delft, The Netherlands, April 21-24, 2015.
References
[1] M. Holick, Vitamin D and bone health, J. Nutr. 126 (1996) 1159S–1164S.
[2] Y. Ma, D. Trump, C. Johnson, Vitamin D in combination cancer treatment, J.
Cancer 1 (2010) 101–107 1.
[3] Y. Ma, D. Trump, C. Johnson, Vitamin D and acute myeloid leukemia, J. Cancer 3
(2010) 101–107.
[4] R. Bouillion, W. Okamura, A. Norman, Structure–function relationships in the
vitamin D endocrine system, Endocr. Rev. 16 (1995) 200–257.
[5] S. Nadkarni, M. Chodynski, A. Corcoran, E. Marcinkowska, G. Brown, A. Kutner,
Double point modiﬁed analogs of vitamin D as potent activators of vitamin D
receptor, Curr. Pharm. Des. 21 (2015) 1741–1763.
[6] A. Aranda, A. Pascual, Nuclear hormone receptors and gene expression,
Physiol. Rev. 81 (2001) 1269–1304.
[7] S. Vaisanen, T. Dunlop, L. Sinkkonen, C. Frank, C. Carlberg, Spatio-temporal
activation of chromatin on the human CYP24 gene promoter in the presence of
1alpha,25-dihydroxyvitamin D3, J. Mol. Biol. 350 (2005) 65–77.
[8] J. Ryynänen, S. Seuter, M. Campbell, C. Carlberg, Gene regulatory scenarios of
primary 1,25-dihydroxyvitamin D3 target genes in a human myeloid leukemia
cell line, Cancers 5 (2013) 1221–1241.
[9] D. Simmons, S. Tan, D. Tenen, A. Nicholson-Weller, B. Seed, Monocyte antigen
CD14 is a phospholipid anchored membrane protein, Blood 73 (1989)
284–289.[10] H. Baurska, A. Klopot, M. Kielbinski, A. Chrobak, E. Wijas, A. Kutner, E.
Marcinkowska, Structure–function analysis of vitamin D2 analogs as potential
inducers of leukemia differentiation and inhibitors of prostate cancer
proliferation, J. Steroid Biochem. Mol. Biol. 126 (2011) 46–54.
[11] H. Baurska, A. Marchwicka, A. Klopot, A. Kutner, E. Marcinkowska, Studies on
the mechanisms of superagonistic pro-differentiating activities of side-chain
modiﬁed analogs of vitamin D2, Oncol. Rep. 28 (2012) 1110–1116.
[12] H. Baurska, M. Kiełbinski, P. Biecek, O. Haus, B. Jazwiec, A. Kutner, E.
Marcinkowska, Monocytic differentiation induced by side-chain modiﬁed
analogs of vitamin D in ex vivo cells from patients with acute myeloid
leukemia, Leuk. Res. 38 (2014) 638–647.
[13] A. Pietraszek, M. Malinska, M. Chodynski, M. Krupa, K. Krajewski, P. Cmoch, K.
Wozniak, A. Kutner, Synthesis and crystallographic study of 1,25-
dihydroxyergocalciferol analogs, Steroids 78 (2013) 1003–1014.
[14] N. Rochel, D. Moras, Structural basis for ligand activity in VDR, in: D. Feldman, J.
Pike, J. Adams (Eds.), Vitamin D, 3rd edition, Academic Press, 2011, pp. 171–191.
[15] R. Gallagher, S. Collins, J. Trujillo, K. McCredie, M. Ahearn, S. Tsai, R. Metzgar, G.
Aulakh, R. Ting, F. Ruscetti, R. Gallo, Characterization of the continuous,
differentiating myeloid cell line (HL-60) from a patient with acute
promyelocytic leukemia, Blood 54 (1979) 713–733.
[16] R. Morosetti, D. Park, A. Chumakov, I. Grillier, M. Shiohara, A. Gombart, T.
Nakamaki, K. Weinberg, H. Koefﬂer, A novel, myeloid transcription factor C/
EBPepsilon, is upregulated during granulocytic, but not monocytic,
differentiation, Blood 90 (1997) 2591–2600.
[17] A. Racz, J. Barsony, Hormone-dependent translocation of vitamin D receptors
is linked to transactivation, J. Biol. Chem. 274 (1999) 19352–19360.
[18] E. Marcinkowska, E. Garay, E. Gocek, A. Chrobak, X. Wang, G. Studzinski,
Regulation of C/EBPb isoforms by MAPK pathways in HL60 cells induced to
differentiate by 1,25-dihydroxyvitamin D3, Exp. Cell Res. 312 (2006)
2054–2065.
[19] G. Studzinski, X. Wang, Y. Ji, Q. Wang, Y. Zhang, A. Kutner, J. Harrison, The
rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/
EBP pathway, J. Steroid Biochem. Mol. Biol. 97 (2005) 47–55.
[20] Y. Ji, G. Studzinski, Retinoblastoma protein and CCAAT/Enhancer-binding
protein b are required for 1,25-dihydroxyvitamin D3-induced differentiation
of HL60 cells, Cancer Res. 64 (2004) 370–377.
[21] B. Lehmann, HaCaT cell line as a model system for vitamin D3 metabolism in
human skin, J. Invest. Dermatol. 108 (1997) 78–82.
[22] E. van Etten, C. Mathieu, Immunoregulation by 1,25-dihydroxyvitamin D3:
basic concepts, J. Steroid Biochem. Mol. Biol. 97 (2005) 93–101.
[23] M. Haussler, C. Haussler, L. Bartik, G. Whitﬁeld, J. Hsieh, S. Slater, P. Jurutka,
Vitamin D receptor: molecular signaling and actions of nutritional ligands in
disease prevention, Nutr. Rev. 66 (Suppl. 2) (2008) S98–112.
